Numinus Wellness Inc. acknowledged President Donald Trump’s Executive Order directing United States federal agencies to accelerate research, access, and regulatory review for psychedelic-based treatments, including psilocybin, ibogaine, MDMA, and LSD. The order directs the FDA to prioritize review of psychedelics with Breakthrough Therapy designation, establishes new investigational access pathways for eligible patients, and commits $50 million in federal support for states developing psychedelic treatment programs.
Payton Nyquvest, Founder and Executive Chairman of Numinus Wellness, stated: “Friday’s executive order is a genuine inflection point. But inflection points don’t automatically translate into patient access. What comes next is continued hard work - the trials, the training, the site readiness, the reimbursement infrastructure, the operational systems that turn regulatory progress into care that actually reaches people.”
Psychedelic-assisted therapies have long shown promise for treatment-resistant depression, PTSD, and addiction. However, operational and commercial infrastructure required to deliver these therapies at scale has lagged behind clinical data. Key needs include trained therapists, qualified clinical research sites, care protocols grounded in real-world administration experience, and operational and reimbursement systems to ensure treatments reach patients sustainably.
Numinus has been developing this infrastructure through Cedar Clinical Research and Numinus Training. Cedar Clinical Research, the company’s specialized clinical trial site operation, is capable of administering nearly 200 psychedelic dosing sessions annually and has accumulated hands-on execution experience in psychedelic research delivery. Numinus Training is currently contracted to deliver therapist training for an active Phase 3 clinical trial program. Therapist supply remains among the most tangible near-term bottlenecks to scaled psychedelic care delivery, with training programs offering real protocol depth and clinical grounding remaining limited.
Numinus recognizes that gaps between regulatory momentum and scaled, accessible care remain significant. Coding frameworks, payer workflows, clinical documentation standards, site readiness, and therapist supply all require sustained investment and expertise. The company positions its clinical research capacity, training infrastructure, and operational implementation knowledge as crucial to providing access to patients who can benefit from the White House’s mandate.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1111005409/Numinus-Wellness-Responds-To-Trump-Executive-Order-On-Psychedelic-Therapies